An observational study in Myotonic Dystrophy 1, sponsored by IRCCS Eugenio Medea. Recruiting at 1 site in Italy. Open to participants aged 1 Year to 35 Years. Per ClinicalTrials.gov, last updated 2024-04-22.
Sponsored by IRCCS Eugenio Medea · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Myotonic Dystrophy with a site in Italy — 11 open to participants now, 13 under way, 5 of them phase 3. Myotonic Dystrophy · Italy.
Among the 19 studies in Myotonic Dystrophy with a site in Italy, this one is one of 3 that started in 2022, is one of 8 observational ones, reaches primary completion later than 0 of the 12 other live ones, and was the 12th registered.
127 studies on the registry are indexed under Myotonic Dystrophy; 50 are open to participants now.
Browse Myotonic Dystrophy studies →11 of the 19 studies in Myotonic Dystrophy with a site in Italy are open now. Recruiting first, the newest first:
Avidity Biosciences, Inc. · Sites in Italy, Australia, Belgium and 7 more countries
Ages 7–16 · Men only
Dyne Therapeutics · Sites in Italy, United States, Australia and 9 more countries
Ages 16+
Lupin Ltd. · Sites in Italy, Belgium, Denmark and 3 more countries
Ages 16+
ARTHEx Biotech S.L. · Sites in Italy, United States, Canada and 4 more countries
Ages 18–64
IRCCS Azienda Ospedaliero-Universitaria di Bologna · Sites in Italy
Ages 12+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 35 Myotonic Dystrophy studies recruiting now, 15 (43%) set no upper age limit and 18 (51%) stop at 75 or younger; 22 take children under 18; 8 take healthy volunteers.
This study: 1 Year to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 3 started in 2022.
This study's planned enrollment of 30 is below the median of 100 across 56 observational studies indexed under Myotonic Dystrophy.
Median enrollment 150 across the 11 interventional studies, 70 across the 8 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 19 have an industry lead sponsor. The 10 most frequent:
IRCCS Eugenio Medea is the lead sponsor of 109 studies on the registry; 52 are open to participants now.
IRCCS Eugenio Medea has 1 study filed under Myotonic Dystrophy — fewer than ten, so there is no comparison to draw.
7 of the studies in Myotonic Dystrophy with a site in Italy that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06523400Phase 3Lupin Ltd.The Efficacy and Safety of Once Daily Mexiletine PR in Patients With Myotonic Dystrophy Type 1 and Type 2 | 2027-06 |
| NCT05224778Virginia Commonwealth UniversityDMCRN-02-001: Assessing Pediatric Endpoints in DM1 | 2026-12 |
| NCT03981575Virginia Commonwealth UniversityEstab Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1) | 2026-12-01 |
| NCT06138743Sarepta Therapeutics, Inc.Study of SRP-1003 in Participants With Type 1 Myotonic Dystrophy | 2026-12-31 |
| NCT06185764Vertex Pharmaceuticals IncorporatedA Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1) | 2027-02-02 |
Add all 7 to your calendar (.ics) → With an account.
Among the 19 studies in Myotonic Dystrophy with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The rationale of the study is to collect structured data in the neuropsychological, clinical neuroradiologic and neurorehabilitation fields in children/young people affected by congenital and juvenile myotonic dystrophy. Children affected by the congenital form (CDM1) present important brain alterations present since birth while, on the contrary, patients with the adult form of DM1 often present a degenerative, slowly progressive neurocognitive picture. Promising therapies that aim to correct the molecular mechanism underlying the symptoms of adult forms of DM1 are under development, but their potential role at the level of the nervous system and in particular in forms of CDM1 (which appears to be a distinct disorder of neuronal development) is also to be clarified.
To this end, a better definition of neurocognitive profiles and their evolution is essential for the purposes of evaluating the effectiveness of experimental therapies.
A. Recruitment of patients with a defined diagnosis of Myotonic Dystrophy type 1 (see following inclusion and exclusion criteria)
B) Clinical and cognitive evaluation
administration of a neuropsychological battery, in order to define the level of cognitive functioning and to frame a detailed function-specific profile (multiple sessions to be defined based on the collaboration of the patients) investigating the following areas:
Patients with a defined diagnosis of MYotonic Dystrophy type 1, congenital and juvenile form
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Myotonic Dystrophy type 1 -congenital form Myotonic Dystrophy type 1-infantile form
Diagnostic Test: neurocognitive evaluations
clinical and neurocognitive evaluations neuroradiological evaluation through cerebral magnetic resonance
Also known as: cerebral imaging
Motor function evaluation by Muscular Impairment Rating Scale
Muscular Impairment Rating Scale (MIRS) in assessing patients with myotonic dystrophy type 1 (DM1). The MIRS is a ordinal five-point rating scale, where grade 1 = no clinical muscular impairment; grade 2 = early muscular impairment (clinical myotonia, facial weakness, and weakness of neck flexors) without limb weakness; grade 3 = distal weakness; grade 4 = mild to moderate (3 ≤ core \< 5) proximal weakness; grade 5 = severe (MRC score\<3)proximal weakness proximal weakness
Time frame: through study completion,an average of 2 years
cognitive evaluation by Wechsler Intelligence scale
Wechsler Intelligence scale: mean score 100 SD 15 (SD: Standard Deviation):deficiency when 2 Standard Deviation below average)
Time frame: through study completion,an average of 2 years
cognitive evaluation by Raven Matrices
Raven Matrices , Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency)
Time frame: through study completion,an average of 2 years
cognitive evaluation by Continous Performance Test 3
Continous Performance Test 3: T mean Scores 50 SD 10 (SD: standard deviation) (T=45-59 in range; T =/\>60 below range)
Time frame: through study completion,an average of 2 years
cognitive evaluation by Trail Making Test A-B
Trail Making Test A-B: Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency)
Time frame: through study completion,an average of 2 years
cognitive evaluation by Digit Span and CORSI Test
Digit Span and CORSI Test:Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency)
Time frame: through study completion,an average of 2 years
cognitive evaluation by Rey Figure test
Rey Figure test: Z scores=/\> 0,00 (in range); Z scores =/\< -2,00 (deficiency):
Time frame: through study completion,an average of 2 years
clinical evaluation by Epworth Sleepiness Scale
Epworth Sleepiness Scale: scores from 0 to 24; above 10, clinical risk.
Time frame: through study completion,an average of 2 years
cognitive evaluation by Wisconsin Card Sorting Test
Wisconsin Card Sorting Test: mean score 100 SD 15 (SD: standard deviation) : deficiency when 2 Standard Deviation below average
Time frame: through study completion,an average of 2 years
cognitive evaluation by Tower of London test
Tower of London:mean score 100 SD 15 deficiency when 2 Standard Deviation below average)
Time frame: through study completion,an average of 2 years
cognitive and behavioral evaluation by Minnesota Multiphasic Personality Inventory
Minnesota Multiphasic Personality Inventory- MMPI 2: mean score 50 SD 10 ((SD: standard deviation)
Time frame: through study completion,an average of 2 years
cognitive and behavioral evaluation by Vineland Adaptive Behavior Scales
Vineland Adaptive Behavior Scales mean score 100 SD 15 (SD: standard deviation) :deficiency when 2 Standard Deviation below average
Time frame: through study completion :an average of 2 years
Plan to share: No
No publications or documents are linked to this record.
Ran from Sep 2022 to primary completion in Mar 2024, 18 months.
Of 36 observational studies under Myotonic Dystrophy, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35. This study's 18 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.